Article
Gilead details promising early COVID antiviral data, setting up larger studies
Rating:
0.0
Views:
69
Likes:
1
Library:
1
Gilead Sciences Inc on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value